Nawaz Walji

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

Galina Velikova, Linda Williams, Sarah Willis et al. · The Lancet Oncology · 2018 · 80 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

Madeleine King, Emma Link, Timothy J. Whelan et al. · The Lancet Oncology · 2020 · 52 citations

Medicine, Oncology, Radiation Oncology +14

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

R. Charles Coombes, Holly Tovey, Lucy Kilburn et al. · JAMA Oncology · 2021 · 47 citations · Full text

Medicine, Oncology, Pharmacology +15

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

M.A. Bergamino, Elena López‐Knowles, Gabriele Morani et al. · EBioMedicine · 2022 · 27 citations · Full text

Medicine, Oncology, Pharmacology +15